Segall Bryant & Hamill LLC Sells 19,781 Shares of Galapagos NV (NASDAQ:GLPG)

Segall Bryant & Hamill LLC lessened its stake in Galapagos NV (NASDAQ:GLPG - Free Report) by 2.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 685,867 shares of the biotechnology company's stock after selling 19,781 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 1.04% of Galapagos worth $18,861,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Finepoint Capital LP lifted its stake in Galapagos by 2.8% in the 3rd quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company's stock worth $16,058,000 after purchasing an additional 15,000 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in shares of Galapagos by 31.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company's stock worth $1,352,000 after purchasing an additional 11,777 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Galapagos by 5.9% in the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock worth $711,000 after buying an additional 1,431 shares in the last quarter. Erste Asset Management GmbH bought a new position in Galapagos during the third quarter valued at approximately $410,000. Finally, QRG Capital Management Inc. grew its holdings in Galapagos by 21.7% during the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after buying an additional 1,866 shares in the last quarter. Institutional investors own 32.46% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several brokerages have recently issued reports on GLPG. Barclays reaffirmed an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. TD Cowen lowered shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a research report on Thursday, January 9th. Finally, Morgan Stanley cut shares of Galapagos from an "equal weight" rating to an "underweight" rating and dropped their price objective for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. According to data from MarketBeat, Galapagos has an average rating of "Hold" and an average price target of $25.33.

Galapagos Stock Down 0.2 %

GLPG traded down $0.04 during trading on Friday, reaching $25.46. The company had a trading volume of 81,476 shares, compared to its average volume of 184,823. The business has a 50 day simple moving average of $25.07 and a 200-day simple moving average of $26.91. Galapagos NV has a 52 week low of $22.36 and a 52 week high of $32.57.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.